Recombinant Human Interleukin-17 receptor (IL-17 R)

Recombinant Human Interleukin-17 receptor (IL-17 R) is a valuable tool in research applications focused on immunology, inflammation, autoimmunity, and host-pathogen interactions because it enables precise modulation and interrogation of the IL-17 signaling pathway.

Key reasons to use recombinant IL-17 R in research:

• Blocking IL-17 Signaling: Recombinant IL-17 R, especially in the form of soluble receptor or Fc fusion proteins, acts as a decoy receptor that binds IL-17A and related cytokines, preventing them from interacting with cell-surface IL-17 receptors and thus inhibiting downstream pro-inflammatory signaling. This is critical for dissecting the role of IL-17 in disease models and for validating therapeutic strategies targeting this pathway.

• Studying Inflammatory Mechanisms: IL-17 and its receptor are central to the recruitment of neutrophils and the amplification of inflammatory responses. Using recombinant IL-17 R allows researchers to modulate these processes in vitro and in vivo, helping to clarify the contribution of IL-17 signaling to diseases such as rheumatoid arthritis, psoriasis, and chronic pain.

• Host Defense and Autoimmunity: IL-17 R is required for effective host defense against microbial infections and is implicated in the progression of autoimmune diseases from inflammation to tissue destruction. Recombinant IL-17 R can be used to model or block these processes, providing insights into both protective and pathological roles of IL-17 signaling.

• Therapeutic Target Validation: In preclinical models, administration of recombinant IL-17 R or its fusion proteins has been shown to reduce disease severity in models of arthritis and other inflammatory conditions, supporting its use in drug development and mechanistic studies.

• Biochemical and Cell-based Assays: Recombinant IL-17 R is used in binding assays, neutralization studies, and as a standard or competitor in ELISA and other immunoassays to quantify IL-17 or to screen for inhibitors of the IL-17/IL-17R interaction.

Additional context:

• IL-17 R is broadly expressed on various cell types, including immune and non-immune cells, and mediates the effects of several IL-17 family cytokines.
• The receptor is essential for the activation of downstream signaling pathways such as NF-κB and MAPKs, which regulate the expression of cytokines, chemokines, and other inflammatory mediators.
• Recombinant forms are typically engineered for high purity, low endotoxin, and functional activity, making them suitable for sensitive in vitro and in vivo applications.

In summary, recombinant human IL-17 R is a critical reagent for dissecting IL-17 biology, validating therapeutic targets, and developing new interventions for inflammatory and autoimmune diseases.

Recombinant Human Interleukin-17 receptor (IL-17 R) can be used as a standard for quantification or calibration in ELISA assays specifically designed to measure IL-17 R, provided the assay protocol supports recombinant protein standards.

For ELISA assays targeting IL-17 R (the receptor), recombinant human IL-17 R is commonly supplied as a standard in commercial ELISA development kits. These kits include protocols and reagents optimized for quantifying both natural and recombinant IL-17 R in biological samples. The standard curve generated from serial dilutions of recombinant IL-17 R allows for accurate quantification of IL-17 R concentrations in unknown samples, as long as the assay is validated for this purpose and the recombinant protein is of high purity and properly characterized.

Key considerations:

• Assay specificity: Ensure your ELISA is designed to detect IL-17 R, not IL-17A or other IL-17 family cytokines. Using IL-17 R as a standard in an IL-17A assay would be inappropriate, as the antibodies are specific to the ligand, not the receptor.
• Standard preparation: Follow the recommended protocol for preparing and diluting the recombinant IL-17 R standard. The standard curve should cover the expected concentration range of your samples.
• Matrix effects: If quantifying IL-17 R in complex matrices (e.g., serum, plasma), validate recovery and linearity using the recombinant standard in those matrices, as matrix components can affect assay performance.
• Documentation: Use the provided datasheet or protocol for your specific ELISA kit to ensure compatibility and optimal results.

Summary Table: Use of Recombinant IL-17 R as ELISA Standard

In conclusion: If your ELISA is designed to measure IL-17 R, recombinant human IL-17 R is suitable as a standard for quantification and calibration. Always confirm compatibility with your assay protocol and validate performance in your sample matrix.

Recombinant Human Interleukin-17 receptor (IL-17 R) has been validated in published research for several key applications, primarily in the context of immunology, inflammation, and autoimmune disease models.

Validated Applications in Published Research:

• Bioassays: Recombinant IL-17 R is widely used in cell-based bioassays to study IL-17 signaling, receptor-ligand interactions, and downstream effects such as cytokine and chemokine production, neutrophil recruitment, and inflammatory responses in various human cell types.
• Neutralization/Blocking Studies: It is used to assess the ability of antibodies or small molecules to block IL-17/IL-17R interactions, which is critical for evaluating potential therapeutics targeting the IL-17 pathway in autoimmune and inflammatory diseases.
• ELISA Development: Recombinant IL-17 R has been used as a standard or capture reagent in ELISA assays for the detection and quantification of IL-17 or its receptor in biological samples.
• Mechanistic Studies: Research has employed recombinant IL-17 R to dissect the signaling pathways activated by IL-17, including activation of fibroblasts, endothelial cells, and immune cells, and to study the expression of adhesion molecules and chemokines.
• Disease Modeling: Recombinant IL-17 R is used in preclinical models of diseases such as rheumatoid arthritis, inflammatory bowel disease, psoriasis, and chronic pain to investigate the role of IL-17 signaling and to test the efficacy of IL-17/IL-17R-targeted therapies.

Key Research Contexts:

• Autoimmune and Inflammatory Diseases: Studies have validated its use in models of rheumatoid arthritis, psoriasis, and inflammatory bowel disease, both in vitro (human cells) and in vivo (animal models), to understand disease mechanisms and evaluate therapeutic interventions.
• Neuroinflammation and Pain: IL-17/IL-17R signaling has been studied in the context of chronic pain and neuroinflammation, with recombinant IL-17 R used to demonstrate the pathway’s contribution to pain sensitization and neuroimmune interactions.
• Cancer and Tumor Immunology: Some studies have used recombinant IL-17 R to explore its role in tumor-associated inflammation and immune cell recruitment.

Summary Table:

References to Specific Research:

• Studies have shown IL-17/IL-17R upregulation in rodent models and human samples of chronic pain, and that IL-17R antibodies can attenuate pain and autoimmune disease symptoms.
• Recombinant IL-17 R has been used to demonstrate the efficacy of novel biologics in neutralizing IL-17-driven inflammation in preclinical models of rheumatoid arthritis and IBD.
• It is also used in mechanistic studies to show IL-17RA/C-dependent activation of fibroblasts and endothelial cells, leading to increased cytokine and chemokine expression.

Conclusion:
Recombinant Human IL-17 receptor (IL-17 R) is validated for use in bioassays, neutralization/blocking studies, ELISA development, mechanistic signaling studies, and disease modeling, particularly in the fields of immunology, inflammation, autoimmune disease, and neuroinflammation.

To reconstitute and prepare Recombinant Human Interleukin-17 receptor (IL-17 R, also known as IL-17RA) protein for cell culture experiments, follow these best-practice steps:

1. Reconstitution

   • Briefly centrifuge the vial before opening to ensure all lyophilized protein is at the bottom.
   • Add sterile distilled water or buffer (such as PBS, pH 7.2–7.4) to achieve a final concentration of 0.1–1.0 mg/mL.
   • Gently mix by pipetting up and down or swirling. Do not vortex, as this can denature the protein.
   • Allow the protein to fully dissolve at room temperature for 10–15 minutes.

2. Carrier Protein (Optional but Recommended)

   • For enhanced stability, especially at low concentrations or for long-term storage, add a carrier protein such as 0.1–1% BSA or HSA to the buffer.
   • This is particularly important if you plan to store aliquots or use the protein at concentrations below 0.1 mg/mL.

3. Aliquoting and Storage

   • Aliquot the reconstituted protein into small volumes to avoid repeated freeze-thaw cycles, which can degrade the protein.
   • Store aliquots at 2–8°C for up to one week, or at –20°C to –80°C for long-term storage.
   • Avoid multiple freeze-thaw cycles.

4. Preparation for Cell Culture

   • Before adding to cell culture, dilute the protein to the desired working concentration using cell culture medium or sterile PBS with carrier protein if needed.
   • Filter-sterilize the final solution if sterility is required and the buffer composition allows.

Summary Table: IL-17R Protein Reconstitution and Handling

Additional Notes:

• Always consult the specific product datasheet for any manufacturer-specific recommendations, as buffer composition and protein stability may vary.
• If using for functional assays, confirm activity post-reconstitution using a relevant bioassay.

These guidelines are based on standard protocols for recombinant cytokine receptor proteins and are consistent with published datasheets and technical manuals for IL-17RA/IL-17R.